中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

323 records (took 0.038 seconds)

    Expandable vertebral body replacement device and method
    81.
    发明授权
    Expandable vertebral body replacement device and method 有权

    公开(公告)号：US10653530B2

    公开(公告)日：2020-05-19

    申请号：US15719192

    申请日：2017-09-28

    Applicant: MUSC Foundation for Research Development

    Inventor： Mark Evald Semler ,  Bruce Frankel ,  Joseph Ruscito

    IPC: A61F2/44 ,  A61F2/46 ,  A61F2/30

    Abstract: An expandable vertebral body device, system, instrument, and methods of assembly and using the device, system, and instrument are disclosed. The vertebral body device includes a body with a first end and a second end, a first rotating member rotatably coupled to the first end, a second rotating member rotatably coupled to the second end, a first extension member moveably coupled to the first end, and a second extension member moveably coupled to the second end. The expandable cage system comprises a vertebral body device and an insertion instrument. Methods for assembling and using the vertebral body device and instrument are also disclosed.

    DOPAMINE AGONISTS IN TREATING ALCOHOL USE DISORDERS ASSOCIATED WITH DOPAMINE RECEPTOR ACTIVITY
    84.
    发明申请
    DOPAMINE AGONISTS IN TREATING ALCOHOL USE DISORDERS ASSOCIATED WITH DOPAMINE RECEPTOR ACTIVITY 审中-公开

    公开(公告)号：US20180369238A1

    公开(公告)日：2018-12-27

    申请号：US16017781

    申请日：2018-06-25

    Applicant: MUSC Foundation for Research Development

    Inventor： Raymond F. Anton ,  Joseph P. Schacht

    IPC: A61K31/496 ,  A61P25/32

    Abstract: Disclosed are methods for treating disorders associated with dopamine receptor activity. In some embodiments, the disclosed methods include assaying the nucleic acid from a subject for the genotype of the variable number tandem repeats (VNTR) polymorphism in the dopamine transporter DAT1/SLC6A3 gene, wherein when one or two alleles for 9 tandem repeats is detected a dopamine partial agonist is administered to the subject; and wherein when two alleles for 10 tandem repeats is detected a dopamine modulator is not administered to the subject. Also provided are methods for treating disorders associated with dopamine receptor activity that include genotyping a subject with respect to a COMT polymorphism, a DRD2 polymorphism, a 48-base-pair VNTR polymorphism in DRD4 exon 3, and/or a ANKK1 TaqA1 polymorphism, and methods for detecting susceptibility to dopamine modulator therapy for conditions associated with dopamine receptor activity.

    Antifibrotic effects of oxetanyl sulfoxides
    86.
    发明授权
    Antifibrotic effects of oxetanyl sulfoxides 有权

    公开(公告)号：US09938250B2

    公开(公告)日：2018-04-10

    申请号：US15499535

    申请日：2017-04-27

    Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education ,  MUSC Foundation for Research Development

    Inventor： Peter Wipf ,  Carol A. Feghali-Bostwick

    IPC: C07D305/08

    CPC classification number: C07D305/08 ,  C07D305/06

    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.

Patent Agency Ranking